Nexstim's Navigated Brain Stimulation shown to improve patient outcomes in challenging brain surgery
19 December 2013
Neurosurgeons strongly advocate use of new brain mapping technique
HELSINKI, Finland--(BUSINESS WIRE)—Dec. 19, 2014--The world's leading experts in functional mapping of the brain gathered for the 5th International Symposium on Navigated Brain Stimulation in Neurosurgery on December 13-14th in Berlin, Germany. Since the introduction of Navigated Brain Stimulation (NBS), hundreds of patients with brain disease have benefitted from this new technique for the accurate and non-invasive presurgical localization of the cortical areas in the brain vital for bodily movement and speech.
The first comparative study on the outcome benefits of NBS mapping was published in the October 2013 edition of "Acta Neurochirurgica", where Dr. Thomas Picht et al. (Charité, Berlin) showed that presurgical NBS mapping enabled more frequent and more extensive surgical resection of low-grade glioma tumors in the brain. At the Berlin Symposium, neurosurgeons were informed that two significantly larger outcomes studies on the clinical role of NBS mapping are currently being prepared for publication.
These new studies, one conducted by Professor Peter Vajkoczy´s team at the Department of Neurosurgery, Charité University Hospital, Berlin and the other by Professor Bernhard Meyer of the Department of Neurosurgery, Klinikum rechts der Isar, Technische Universität München (TUM), are ten times the size of the recently published study, with each study comprising hundreds of patients. The Berlin Symposium heard that the results of these extensive studies prove the clinical value of preoperative mapping by NBS for brain lesions near cortical motor areas. Neurosurgeons at Munich and Berlin now strongly advocate the use of NBS in this challenging patient group.
Founded in 2000, Finland-based Nexstim Oy is the world leader in image-guided transcranial magnetic stimulation (TMS). Nexstim has pioneered the technology for brain diagnostics and with FDA-clearance, Nexstim´s Navigated Brain Stimulation (NBS) System is recognized as the emerging standard for pre-operative direct functional mapping. Nexstim´s Navigated Brain Therapy (NBT®) System (CE-marked) enables personalized, non-drug treatment of brain injury and disease using repetitive TMS (rTMS) with accurate and repeatable 3D-guidance of the therapeutic electric field. NBT is initially being studied as an adjunct to physiotherapy in stroke rehabilitation.
For more information:
CEO Janne Huhtala, 358 40 861 5046
Caution to US residents: the NBS System is cleared by the FDA for assessment of the motor and speech cortices for pre-procedural planning. The NBT System is not cleared for marketing in the USA.
Back to Press Releases